CARDIAC ARRAY

Simultaneous measurement of:

• Creatine Kinase-MB (CK-MB)
• Fatty Acid Binding Protein (FABP)
• Myoglobin (Mb)
• Troponin I (cTn I)

Cardiovascular disease is responsible for over 18.5 million deaths each year and costs the global economy over €500 billion. Recent research however has estimated that at least 70% of all patients attending hospital with chest pains do not actually have a cardiac related condition. In many cases such patients are unnecessarily admitted because Acute Myocardial Infarction (AMI) could not be reliably ruled out in the emergency room. 

Current methods used to assess AMI can be unreliable.  Although the ECG is specific it is not sufficient on its own to rule out AMI. Furthermore, the sensitivity of traditional cardiac markers is very much dependent on the time delay between the onset of symptoms and blood sampling. In the past a delay of 10-12 hours has been considered necessary to completely rule out AMI meaning patients often have to be admitted until the necessary time has elapsed. 

A rapid and reliable diagnostic test such as the Randox cardiac array to rule out AMI soon after arrival in the emergency room could potentially reduce the number of unnecessary hospital admissions and save global healthcare providers millions of pounds each year. The Cardiac Array could also help to reduce the estimated 6% of patients who are inappropriately discharged following actual AMI. It can be used to identify those at risk of Acute Coronary Syndrome or as an early indicator of Myocardial Infarction.